BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period
Clarivate Plc released the company’s list of Highly Cited Researchers 2020 that identifies researchers who “demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade.”
Two new companies backed by significant financing that will be used to develop treatments for a wide range of diseases launched: Metagenomi will concentrate on next-generation gene therapies and Kira Pharmaceuticals will tackle complement-mediated diseases.
Intent on growing PerkinElmer’s life sciences portfolio, the company agreed to acquire cell engineering specialist Horizon Discovery Group for $383 million.
The Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer A. Doudna for their discovery and development of CRISPR gene editing.
Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.
Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).
Frost & Sullivan IDs Five New Technologies to Power Research Across Preclinical Disease Models Published: July 16, 2020 BioSpace When the CEOs of young, innovative biotech companies discuss how their new technologies came to be, they almost inevitably mention a convergence of technologies that was pivotal in transforming an idea into a therapeutic, diagnostic, tool […]
Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.
Bristol-Myers Squibb is taking aim at harnessing CRISPR-based solutions to treat certain cancers with a $65 million collaboration with Montreal-based Repare Therapeutics.